ROR1 sustains caveolae and survival signalling as a scaffold of cavin-1 and caveolin-1

Nature Communications

Volumn 7, Issue , 2016, Pages

  Yamaguchi, Tomoya ^a   Lu, Can ^a   Ida, Lisa ^a   Yanagisawa, Kiyoshi ^a   Usukura, Jiro ^b   Cheng, Jinglei ^a   Hotta, Naoe ^a   Shimada, Yukako ^a   Isomura, Hisanori ^a   Suzuki, Motoshi ^a   Fujimoto, Toyoshi ^a   Takahashi, Takashi ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CAVEOLIN 1; CAVIN 1; CELL MEMBRANE PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; PROTEIN TYROSINE KINASE; RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR; RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR 1; SCATTER FACTOR RECEPTOR; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CAV1 PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; PTRF PROTEIN, HUMAN; RNA BINDING PROTEIN; ROR1 PROTEIN, HUMAN;

CANCER; DEGRADATION; ENZYME ACTIVITY; INHIBITION; INHIBITOR; RESPIRATORY DISEASE; SENSORY SYSTEM; SURVIVAL;

ARTICLE; CANCER PATIENT; CAVEOLA; CELL LINEAGE; CELL SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; LUNG ADENOCARCINOMA; LUNG CANCER CELL LINE; LYSOSOME; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; ADENOCARCINOMA; ANTAGONISTS AND INHIBITORS; GENETICS; LUNG NEOPLASMS; METABOLISM; PHOSPHORYLATION; PROTEIN MICROARRAY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CAVEOLIN 1; CELL LINE, TUMOR; HUMANS; LUNG NEOPLASMS; PHOSPHORYLATION; PROTEIN ARRAY ANALYSIS; PROTEIN-TYROSINE KINASES; RECEPTOR TYROSINE KINASE-LIKE ORPHAN RECEPTORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA-BINDING PROTEINS; SIGNAL TRANSDUCTION;

EID: 84953240034     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms10060     Document Type: Article

References (49)

1. Parton, R. G., del Pozo, M. A. Caveolae as plasma membrane sensors, protectors and organizers. Nat. Rev. Mol. Cell Biol. 14, 98-112 (2013).
2. Hansen, C. G., Nichols, B. J. Exploring the caves: cavins, caveolins and caveolae. Trends. Cell Biol. 20, 177-186 (2010).
3. Briand, N., Dugail, I., Le Lay, S. Cavin proteins: new players in the caveolae field. Biochimie 93, 71-77 (2011).
4. Strålfors, P. in Advances in Molecular and Cell Biology vol. 36 (eds Frank, P., Lisanti, M.) 141-169 (Elsevier, 2005).
5. Hill, M. M. et al. PTRF-Cavin, a conserved cytoplasmic protein required for caveola formation and function. Cell 132, 113-124 (2008).
6. Liu, L., Pilch, P. F. A critical role of cavin (polymerase I and transcript release factor) in caveolae formation and organization. J. Biol. Chem. 283, 4314-4322 (2008).
7. Ho, C. C. et al. Up-regulated caveolin-1 accentuates the metastasis capability of lung adenocarcinoma by inducing filopodia formation. Am. J. Pathol. 161, 1647-1656 (2002).
8. Luanpitpong, S. et al. Caveolin-1 regulates lung cancer stem-like cell induction and p53 inactivation in carbon nanotube-driven tumorigenesis. Oncotarget 5, 3541-3554 (2014).
9. Sunaga, N. et al. Different roles for caveolin-1 in the development of non-small cell lung cancer versus small cell lung cancer. Cancer Res. 64, 4277-4285 (2004).
10. Niederst, M. J., Engelman, J. A. Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer. Sci. Signal. 6, re6 (2013).
11. Chong, C. R., Janne, P. A. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat. Med. 19, 1389-1400 (2013).
12. Yano, S. et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res. 68, 9479-9487 (2008).
13. Guix, M. et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J. Clin. Invest. 118, 2609-2619 (2008).
14. Turke, A. B. et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17, 77-88 (2010).
15. Yamaguchi, T. et al. NKX2-1/TITF1/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma. Cancer Cell 21, 348-361 (2012).
16. Yamaguchi, T., Hosono, Y., Yanagisawa, K., Takahashi, T. NKX2-1/TTF-1: an enigmatic oncogene that functions as a double-edged sword for cancer cell survival and progression. Cancer Cell 23, 718-723 (2013).
17. Drab, M. et al. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science 293, 2449-2452 (2001).
18. Razani, B. et al. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J. Biol. Chem. 276, 38121-38138 (2001).
19. Tang, Z. et al. Molecular cloning of caveolin-3, a novel member of the caveolin gene family expressed predominantly in muscle. J. Biol. Chem. 271, 2255-2261 (1996).
20. Nichols, B. J. A distinct class of endosome mediates clathrin-independent endocytosis to the Golgi complex. Nat. Cell Biol. 4, 374-378 (2002).
21. Nomura, R., Fujimoto, T. Tyrosine-phosphorylated caveolin-1: immunolocalization and molecular characterization. Mol. Biol. Cell 10, 975-986 (1999).
22. Fujita, A., Fujimoto, T., Ozato-Sakurai, N., Suzuki, H. A method for efficient observation of intracellular membranes of monolayer culture cells by quickfreeze and freeze-fracture electron microscopy. J. Electron Microsc. (Tokyo) 61, 441-446 (2012).
23. Usukura, J. et al. Use of the unroofing technique for atomic force microscopic imaging of the intra-cellular cytoskeleton under aqueous conditions. J. Electron Microsc. (Tokyo) 61, 321-326 (2012).
24. Brown, D. A., Rose, J. K. Sorting of GPI-anchored proteins to glycolipidenriched membrane subdomains during transport to the apical cell surface. Cell 68, 533-544 (1992).
25. Fujimoto, T. Calcium pump of the plasma membrane is localized in caveolae. J. Cell Biol. 120, 1147-1157 (1993).
26. Schermelleh, L., Heintzmann, R., Leonhardt, H. A guide to super-resolution fluorescence microscopy. J. Cell Biol. 190, 165-175 (2010).
27. Hojjat-Farsangi, M. et al. The receptor tyrosine kinase ROR1-An oncofetal antigen for targeted cancer therapy. Semin. Cancer Biol. 29, 21-31 (2014).
28. Kobayashi, S. et al. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res. 65, 7096-7101 (2005).
29. Bean, J. et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc. Natl Acad. Sci. USA 104, 20932-20937 (2007).
30. Yamada, T. et al. Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer. Clin. Cancer Res. 16, 174-183 (2010).
31. Fukuda, T. et al. Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. Proc. Natl Acad. Sci. USA 105, 3047-3052 (2008).
32. Hayer, A., Stoeber, M., Bissig, C., Helenius, A. Biogenesis of caveolae: stepwise assembly of large caveolin and cavin complexes. Traffic 11, 361-382 (2010).
33. Parpal, S., Karlsson, M., Thorn, H., Stralfors, P. Cholesterol depletion disrupts caveolae and insulin receptor signaling for metabolic control via insulin receptor substrate-1, but not for mitogen-activated protein kinase control. J. Biol. Chem. 276, 9670-9678 (2001).
34. Head, B. P. et al. Loss of caveolin-1 accelerates neurodegeneration and aging. PLoS ONE 5, e15697 (2010).
35. Govender, P. et al. Cavin1; a regulator of lung function and macrophage phenotype. PLoS ONE 8, e62045 (2013).
36. Liu, L. et al. Deletion of Cavin/PTRF causes global loss of caveolae, dyslipidemia, and glucose intolerance. Cell Metab. 8, 310-317 (2008).
37. Fernandez-Rojo, M. A. et al. Caveolin-1 orchestrates the balance between glucose and lipid-dependent energy metabolism: implications for liver regeneration. Hepatology 55, 1574-1584 (2012).
38. Tomassian, T. et al. Caveolin-1 orchestrates TCR synaptic polarity, signal specificity, and function in CD8 T cells. J. Immunol. 187, 2993-3002 (2011).
39. Patel, H. H. et al. Mechanisms of cardiac protection from ischemia/reperfusion injury: a role for caveolae and caveolin-1. FASEB J. 21, 1565-1574 (2007).
40. Cao, H., Alston, L., Ruschman, J., Hegele, R. A. Heterozygous CAV1 frameshift mutations (MIM 601047) in patients with atypical partial lipodystrophy and hypertriglyceridemia. Lipids Health Dis. 7, 3 (2008).
41. Wilson, T. R. et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487, 505-509 (2012).
42. Gentile, A., Lazzari, L., Benvenuti, S., Trusolino, L., Comoglio, P. M. Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis. Cancer Res. 71, 3132-3141 (2011).
43. Zhang, S. et al. The onco-embryonic antigen ROR1 is expressed by a variety of human cancers. Am. J. Pathol. 181, 1903-1910 (2012).
44. Zhang, S. et al. ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth. PLoS ONE 7, e31127 (2012).
45. Zhang, S. et al. Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy. Proc. Natl Acad. Sci. USA 111, 17266-17271 (2014).
46. Bicocca, V. T. et al. Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia. Cancer Cell 22, 656-667 (2012).
47. Daneshmanesh, A. H. et al. Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy. Int. J. Cancer 123, 1190-1195 (2008).
48. Baskar, S. et al. Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia. Clin. Cancer Res. 14, 396-404 (2008).
49. Fujimoto, T., Fujimoto, K. Metal sandwich method to quick-freeze monolayer cultured cells for freeze-fracture. J. Histochem. Cytochem. 45, 595-598 (1997).